Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Overcoming Endocrine Resistance in Metastatic Breast Cancer: A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy

NCT00688194 is registered in ClinicalTrials.gov with Gruppo Italiano Mammella (GIM) as lead sponsor.

NCT NCT00688194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00688194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Overcoming Endocrine Resistance in Metastatic Breast Cancer: A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy
Lead sponsor
Gruppo Italiano Mammella (GIM)
Phase
Phase 3
Overall status
Unknown status
Start date
May 31, 2008
Completion date
Not reported
Enrollment
396 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer